Would you consider adjuvant capecitabine in a premenopausal patient with HR-positive inflammatory breast cancer who had residual disease after neoadjuvant chemotherapy?  

Yes, I would consider adjuvant capecitabine for a patient with residual invasive disease after standard neoadjuvant chemotherapy (NAC) for HR+ inflammatory breast cancer. Given the uncertainties about the absolute benefit in recurrence and mortality in this specific situation, I would discuss this w...